Fungal pneumonias in transplant recipients

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 3, 2003, Pages 193-198

  Bag, Remzi ^a,b,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

^d Pulmonary Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; LUNG MYCOSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION;

ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG THERAPY, COMBINATION; FEMALE; FUNGEMIA; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTIONS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 0037403908     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200305000-00007     Document Type: Review

References (89)

1. Soubani AO, Chandrasekar PH: The clinical spectrum of pulmonary aspergillosis. Chest 2002, 121:1988-1999. Concise article about the clinical presentation, diagnostic methods, and approach to management of the spectrum of pulmonary aspergillosis.
2. Anaissie EJ, Costa SF: Nosocomial aspergillosis is waterborne. Clin Infect Dis 2001, 33:1546-1548.
3. Anaissie EJ, Stratton SL, Dignani MC, et al.: Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002, 35:E86-E88.
4. Anaissie EJ, Penzak SR, Dignani MC: The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med 2002, 162:1483-1492.
5. Anaissie EJ, Stratton SL, Dignani MC, et al.: Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002, 34:780-789.
6. Anaissie EJ, Kuchar RT, Rex JH, et al.: Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Olin Infect Dis 2001, 33:1871-1878.
7. Pegues DA, Lasker BA, McNeil MM, et al.: Cluster of cases of invasive aspergillosis in a transplant intensive care unit: evidence of person-to-person airborne transmission. Clin Infect Dis 2002, 34:412-416.
8. McNeil MM, Nash SL, Hajjeh RA, et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001, 33:641-647.
9. Wakayama M, Shibuya K, Ando T, et al.: Deep-seated mycosis as a complication in bone marrow transplantation patients. Mycoses 2002, 45:146-151.
10. Krcmery V, Barnes AJ: Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002, 50:243-260.
11. Oliveira JS, Kerbauy FR, Colombo AL, et al.: Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Braz J Med Biol Res 2002, 35:789-798.
12. Marr KA, Carter RA, Crippa F, et al.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917. Review of the epidemiology of mould infections in 5589 patients with hematopoietic stem cell transplantation at the Fred Hutchinson Cancer Res Center (Seattle) from 1985 through 1999.
13. Chouaki T, Lavarde V, Lachaud L, et al.: Invasive infections due to Trichoderma species: report of 2 cases, findings of in vitro susceptibility testing, and review of the literature. Clin Infect Dis 2002, 35:1360-1367.
14. Nunley DR, Gal AA, Vega JD, et al.: Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest 2002, 122:1185-1191.
15. Benito N, Moreno A, Puig J, Rimola A: Alternariosis after liver transplantation. Transplantation 2001, 72:1840-1843.
16. Castiglioni B, Sutton DA, Rinaldi MG, et al.: Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 2002, 81:333-348.
17. Raj R, Frost AE: Scedosporium apiospermum fungemia in a lung transplant recipient. Chest 2002, 121:1714-1716.
18. Tamm M, Malouf M, Glanville A: Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis 2001, 3:189-194.
19. De Medeiros CR, Bleggi-Torres LF, Faoro LN, et al.: Cavernous sinus thrombosis caused by zygomycosis after unrelated bone marrow transplantation. Transpl Infect Dis 2001, 3:231-234.
20. Keyser A, Schmid FX, Linde HJ, et al.: Disseminated Cladophialophora bantiana infection in a heart transplant recipient. J Heart Lung Transplant 2002, 21:503-505.
21. Singh N: Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001, 33:1692-1696.
22. Toor AA, Van Burik JA, Weisdorf DJ: infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone Marrow Transplant 2001, 28:1129-1134.
23. Alangaden GJ, Wahiduzzaman M, Chandrasekar PH: Aspergillosis: The most common community-acquired pneumonia with gram- negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis 2002, 35:659-664.
24. Cornet M, FLeury L, Maslo C, et al.: Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002, 51:288-296.
25. Benjamin DK Jr, Miller WC, Bayliff S, et al.: Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002, 21:227-234.
26. Baddley JW, Stroud TP, Salzman D, Pappas PG: Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001, 32:1319-1324. Single-institution review of invasive mold infections, confirming high risk associated with period of GVHD.
27. Benjamin DK Jr, Miller WC, Bayliff S, et al.: infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002, 21:227-234.
28. Junghanss C, Marr KA: Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis 2002, 15:347-353.
29. Martino R, Subira M, Rovira M, et al.: Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002, 116:475-482.
30. Abbott KC, Hypolite I, Poropatich RK, et al.: Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001, 3:203-211.
31. Mehrad B, Paciocco G, Martinez FJ, Ojo TC: Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001, 119:169-175. Single center experience and review of the literature regarding the incidence and natural history of Aspergillus colonization and infection in lung transplant recipients, and the impact of therapy on tracheobronchitis and invasive infection.
32. Winston DJ, Busuttil RW: Randomized controlled trial of oral itraconzole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002, 74:688-695.
33. Perfect JR, Cox GM, Lee JY, et al.: The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001, 33:1824-1833.
34. Altiparmak MR, Apaydin S, Trablus S, et al.: Systemic fungal infections after renal transplantation. Scand J Infect Dis 2002, 34:284-288.
35. Nichols WG, Corey L, Gooley T, et al.: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:2?3-282.
36. Al-Kattan K, Ashour M, Hajjar W, et al.: Surgery for pulmonary aspergilloma in post-tuberculous vs. immune- compromised patients. Eur J Cardiothorac Surg 2001, 20:728-733.
37. Oren I, Goldstein N: Invasive pulmonary aspergillosis. Curr Opin Pulm Med 2002, 8:195-200.
38. Patterson TF, Kirkpatrick WR, White M, et al.: Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore) 2000, 79:250-260.
39. Nathan SD, Shorr AF, Schmidt ME, Burton NA: Aspergillus and endobronchial abnormalities in lung transplant recipients. Chest 2000, 118:403-407.
40. Kenney HH, Agrons GA, Shin JS: Best cases from the AFIP: invasive pulmonary aspergillosis: radiologic and pathologic findings. Radiographics 2002, 22:1507-1510.
41. Hauggaard A, Ellis M, Ekelund L: Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 2002, 43:292-298.
42. Kim K, Lee MH, Kim J, et al.: Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol 2002, 71:75-79.
43. Reichenberger F, Habicht J, Matt P, et al.: Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999, 24:1195-1199.
44. Buchheidt D, Baust C, Skladny H, et al.: Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin Infect Dis 2001, 33:428-435.
45. Raad I, Hanna H, Huaringa A, et al.: Diagnosis of Invasive Pulmonary Aspergillosis Using Polymerase Chain Reaction-Based Detection of Aspergillus in BAL. Chest 2002, 121:1171-1176.
46. Maertens J, Van Eldere J, Verhaegen J, et al.: Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002, 186:1297-1306.
47. Maertens J, Verhaegen J, Demuynck H, et al.: Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999, 37:3223-3228.
48. Becker MJ, de Marie S, Willemse D, et al.: Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000, 38:1434-1438.
49. Martino R, Subira M: Invasive fungal infections in hematology: new trends. Ann Hematol 2002, 81:233-243.
50. Bialek R, Moshous D, Casanova JL, et al.: Aspergillus antigen and PCR assays in bone marrow transplanted children. Eur J Med Res 2002, 7:177-180.
51. Hoffer FA, Gow K, Flynn PM, Davidoff A: Accuracy of percutaneous lung biopsy for invasive pulmonary aspergillosis. Pediatr Radiol 2001, 31:144-152.
52. Rex JH, Walsh TJ, Sobel JD, et al.: Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:662-678.
53. Bodey GP, Mardani M, Hanna HA, et al.: The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002, 112:380-385.
54. Ellis D: Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002, 49(suppl 1):7-10.
55. Pappas PG, Perfect JR, Cloud GA, et al.: Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001, 33:690-699. Retrospective study of demographics, therapeutic approach, and poor prognostic factors in cryptococcosis in 15 centers in the US.
56. Vilchez RA, Fung J, Kusne S: Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002, 2:575-580. An overview of the changes in the incidence, clinical manifestations, and management of cryptococcosis in organ transplant recipients.
57. Vilchez RA, Linden P, Lacomis J, et al.: Acute respiratory failure associated with pulmonary cryptococcosis in non-AIDS patients. Chest 2001, 119:1865-1869.
58. Brandt ME, Pfaller MA, Hajjeh RA, et al.: Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001, 45:3065-3069.
59. O'Bryan TA, Browne FA, Schonder JF: Scedosporium apiospermum (Pseudallescheria boydii) endocarditis. J Infect 2002, 44:189-192.
60. Revankar SG, Patterson JE, Sutton DA, et al.: Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002, 34:467-476. A total of 72 cases are reviewed. Scedosporium prolificans is by far the most common.
61. Nonaka D, Yfantis H, Southall P, Sun CC: Pseudallescheriasis as an aggressive opportunistic infection in a bone marrow transplant recipient. Arch Pathol Lab Med 2002, 126:207-209.
62. Meletiadis J, Meis JF, Mouton JW, et al.: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002, 46:62-68.
63. Al Refai M, Duhamel C, Le Rochais JP, Icard P: Lung scedosporiosis: a differential diagnosis of aspergillosis. Eur J Cardiothorac Surg 2002, 21:938-939.
64. Gil-Lamaignere C, Roilides E, Mosquera J, et al.: Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002, 46:2234-2237.
65. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002, 34:1648-1650.
66. Kanda Y, Yamamoto R, Chizuka A, et al.: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000, 89:1611-1625.
67. Rex JH, Walsh TJ, Nettleman M, et al.: Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 2001, 33:95-106.
68. Dykewicz CA: Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001, 33:139-144.
69. MacMillan ML, Goodman JL, Defer TE, Weisdorf DJ: Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002, 112:369-379. Low-dose (200 mg daily) fluconazole prophylaxis had similar efficacy in this randomized trial in bone marrow transplantation in both children and adults.
70. Safdar A, Van Rhee F, Henslee-Downey JP, et al.: Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001, 28:873-878.
71. Reichenspurner H, Gamberg P, Nitschke M, et al.: Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997, 29:627-628.
72. Palmer SM, Drew RH, Whitehouse JD, et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001, 72:545-548. First pilot study documenting the safety and tolerability of aerosolized amphotericin B lipid complex as prophylaxis for aspergillosis after lung transplantation.
73. Romero AJ, Pogamp PL, Nilsson LG, Wood N: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002, 71:226-234.
74. Dannaoui E, Borel E, Monier M-F, et al.: Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001, 47:333-340.
75. Mosquera J, Denning DW: Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2002, 46:556-557.
76. Verweij PE, Te Dorsthorst DTA, Rijs AJMM, et al.: Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002, 40:2648-2650.
77. Boogaerts M, Winston DJ, Bow EJ, et al.: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001, 135:412-422.
78. Walsh TJ, Pappas P, Winston DJ, et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
79. Denning DW, Ribaud P, Milpied N, et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
80. HERBRECHT R, DENNING DW, PATTERSON TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
81. Koss T, Bagheri B, Zeana C, et al.: Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol 2002, 46:945-947.
82. Graybill JR: The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001, 55:633-638.
83. Arathoon EG: Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001, 14:685-691.
84. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245-247.
85. Stone EA, Fung HB, Kirschenbaum HL: Caspofungin: an echinocandin anti-fungal agent. Clin Ther 2002, 24:329,351-377.
86. Walsh TJ, Finberg RW, Arndt C, et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764-771.
87. Bowden R, Chandrasekar P, White MH, et al.: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002, 35:359-366.
88. Eriksson U, Seifert B, Schaffner A: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001, 322:579-582.
89. Casadevall A, Pirofski LA: Adjunctive immune therapy for fungal infections. Clin Infect Dis 2001, 33:1048-1056. Review of immunotherapies and their potential future role in fungal infections.